[Immuno-Oncology Summit 2018] Immune Checkpoint Inhibitor Profiling and Biomarker Identification Using Human Primary Cell BioMAP®Oncology Systems

[Immuno-Oncology Summit 2018] Immune Checkpoint Inhibitor Profiling and Biomarker Identification Using Human Primary Cell BioMAP®Oncology Systems
File Name/Number:
Immuno-Oncology Summit 2018

Year:
2018

With recent advances in cancer immunotherapies, especially the immune checkpoint inhibitors,  the ability to evaluate candidate compounds for immuno-oncology (I-O) potential in complex biological networks is becoming increasingly important. BioMAP Oncology systems consist of physiologically-relevant co-cultures of human primary fibroblasts or endothelial cells, human primary immune cells, and cancer cell lines to model inflamed stromal or vascular host-tumor microenvironments (TME). These systems are used to statistically evaluate the impact of agents on protein biomarkers, based on a historical vehicle control significance envelope. Here, we investigated a panel of anti-cancer drugs with diverse mechanisms-of-action (MoA), including immune checkpoint inhibitors, EGFR-kinase inhibitors, and microtubule stabilizers, in the BioMAP colorectal cancer panel (CRC) as well as in the BioMAP Diversity PLUS®panel, which models a broad scope of